Story
Revolution Medicines Named Top Biotech Pick by BofA on Cancer Drug Approval
Summary
BofA Securities designated Revolution Medicines (RVMD) as its top U.S. biotech pick and raised its price target to $265, citing the recent approval and strong launch potential of its cancer therapy, Rasonque.
BofA Securities has named Revolution Medicines (RVMD) its top pick in the U.S. biotechnology sector, raising its price target for the company amid a broader industry rally and a key drug approval.
Rationale for the Upgrade
In a note to clients, BofA raised its price target on Revolution Medicines to $265 from a previous $225, reiterating a Buy rating. The bank's conviction is centered on the recent approval of daraxonrasib, marketed as Rasonque, for previously treated metastatic pancreatic ductal adenocarcinoma.
BofA highlighted the company's readiness for a U.S. launch. An expanded access program has already supplied the drug to physicians on behalf of more than 2,000 patients, a factor the bank believes will support rapid commercial uptake. Key details include:
- Pricing: Rasonque is priced at $39,800 per 30-day supply.
- Financial Position: The company holds a strong cash position of $3.9 billion to support commercialization and parallel clinical programs.
Sector-Wide Trends
AdThe designation comes as the biotechnology industry continues to outperform the broader market. According to BofA, the SPDR S&P Biotech ETF (XBI) has gained 22.4% year-to-date, significantly outpacing the S&P 500's 11.4% return over the same period.
The investment bank observed a distinct shift in investor preference within the sector. Companies with positive clinical data or approaching significant trial readouts have generally seen stronger stock performance than commercial-stage firms focused on product launches. While a supportive capital environment continues to reward positive clinical results, BofA expects investors to apply greater scrutiny to the execution of new drug launches.
Pipeline and Analyst Outlook
BofA Securities views Revolution Medicines as having the "deepest clinical and commercial lead in RAS-targeted cancer therapies," with multiple opportunities to extend that advantage over the next 12 months. Upcoming catalysts include data from zoldonrasib combinations and elironrasib studies in non-small cell lung cancer.
Other Wall Street firms have also issued positive updates on the company. Morgan Stanley recently initiated coverage with an Overweight rating, while several other firms, including Needham, Guggenheim, and UBS, have also raised their price targets on RVMD.
Read next
More on Stocks
AI Infrastructure Firm Accelevation Sets IPO Terms, Targeting Up to $5.4 Billion Valuation
AI infrastructure provider Accelevation is targeting a valuation of up to $5.37 billion and aims to raise as much as $720 million in its upcoming U.S. initial public offering, capitalizing on strong investor interest in artificial intelligence.
Quest, Labcorp Shares Tumble on Proposed Medicare Reimbursement Cuts
Shares of Quest Diagnostics and Labcorp fell sharply in premarket trading after the Centers for Medicare & Medicaid Services proposed significant cuts to laboratory testing fees, set to begin in 2027.
Roche's Obesity Drug Enicepatide Shows 15.5% Weight Loss in Mid-Stage Diabetes Trial
Swiss drugmaker Roche announced its experimental obesity drug, enicepatide, helped patients with type 2 diabetes achieve an average 15.5% weight loss and significant blood sugar control in a mid-stage study.
DoorDash to Pay $131.5 Million in NYC Settlement Over Worker Pay Issues
Food delivery giant DoorDash has agreed to a $131.5 million settlement with New York City following a probe that found the company underpaid or delayed payments to its delivery workers.